Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Gains from Investment Securities: 2010-2024

Historic Gains from Investment Securities for CorMedix (CRMD) over the last 13 years, with Dec 2024 value amounting to $289,622.

  • CorMedix's Gains from Investment Securities was N/A to -$4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 million, marking a year-over-year change of. This contributed to the annual value of $289,622 for FY2024, which is 45.95% up from last year.
  • CorMedix's Gains from Investment Securities amounted to $289,622 in FY2024, which was up 45.95% from $198,443 recorded in FY2023.
  • CorMedix's Gains from Investment Securities' 5-year high stood at $4.5 million during FY2022, with a 5-year trough of $183,148 in FY2020.
  • Over the past 3 years, CorMedix's median Gains from Investment Securities value was $289,622 (recorded in 2024), while the average stood at $1.6 million.
  • Per our database at Business Quant, CorMedix's Gains from Investment Securities soared by 1,733.56% in 2021 and then crashed by 95.54% in 2023.
  • CorMedix's Gains from Investment Securities (Yearly) stood at $183,148 in 2020, then skyrocketed by 1,733.56% to $3.4 million in 2021, then skyrocketed by 32.64% to $4.5 million in 2022, then crashed by 95.54% to $198,443 in 2023, then surged by 45.95% to $289,622 in 2024.